DURHAM, N.C., May 19, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will present Beginning of The End (BOTE) clinical data from its previously ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 30% of berdazimer gel-treated patients had complete ...
– The B-SIMPLE4 pivotal Phase 3 clinical study of berdazimer gel, 10.3% (SB206) is the largest interventional trial of molluscum contagiosum ("molluscum") (n=891)1 – – Company previously reported ...
DURHAM, N.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), announced today that the Company has submitted a New Drug Application (NDA) to the U.S. Food and ...
Treatment with a berdazimer gel, a novel, topical nitric oxide–releasing agent, significantly improved clearance of molluscum contagiosum lesions, compared with placebo, in a study of 891 individuals ...
Molluscum contagiosum (MC), a viral skin infection caused by the poxvirus, often presents challenges in treatment due to limited therapeutic options. However, a potential breakthrough has emerged with ...
Please provide your email address to receive an email when new articles are posted on . Berdazimer gel 10.3% was well tolerated with minimal systemic exposure in the treatment of children with ...
– Novan advancing berdazimer gel, 10.3% toward New Drug Application (NDA) submission for molluscum contagiosum, targeted before end of 2022 DURHAM, N.C., May 19, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results